The hope for neglected diseases: R&D incentives
Neglected diseases are neglected because they cannot generate enough return on R&D to pharmaceutical firms. This paper analyzes and compares existing proposals for public intervention in R&D for neglected diseases. Incentives for neglected diseases are comprehensively evaluated based on seventeen selected criteria grouped into four categories: efficiency, feasibility, fairness, and sustainability. Our conclusion is that public-private partnerships coordinated through a centralized service platform have the highest potential to satisfy the criteria for the successful development..
|Date of creation:||Aug 2010|
|Date of revision:|
|Contact details of provider:|| Postal: +44-(0)20-7882-3167|
Web page: http://www.busman.qmul.ac.uk/research/cgr/index.html
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:cgs:wpaper:35. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Pedro S. Martins)
If references are entirely missing, you can add them using this form.